as Dave (?) pointed at earlier, there are the derivatives of the collaboration with Genome Therapeutics. The last wording that I could find, prior to filing of the new KDUS 10-K, was from the '98 GENE 10-K......
CADUS PHARMACEUTICAL CORP.
In July 1998, the Company entered into a collaboration agreement with Cadus
to identify and commercially develop novel drug discovery targets. The
collaboration combines the Company's strength in identifying, sequencing and
cloning novel, full-length genes with Cadus' expertise in functional genomics
and drug discovery assay development. The collaboration will also make use of
the Company's gene expression technologies.
Through the agreement, researchers will initially focus on the discovery of
novel G protein-coupled receptors (GPCRs) and may expand their efforts to
include other target class of interest. The two companies would share in the
proceeds from any new alliances that make use of targets identified within the
collaboration.
As of the end of the fiscal year, several novel receptors had been
identified.
This is the latest........
On July 25, 1998, the Company entered into a collaboration agreement
with Genome Therapeutics Corporation ("GTC"), which has bioinformatics
technologies and know-how that it uses to identify and sequence orphan G
Protein-coupled receptors. Pursuant to the collaboration, the Company and Genome
Therapeutics Corporation identified and isolated fifty-six (56) human orphan G
Protein-coupled receptors. The rights to such fifty-six (56) human orphan G
Protein-coupled receptors are owned jointly by the Company and GTC. Each of the
Company and GTC will share in any research funding, equity investments, license
fees, milestone payments and royalties that may be received from third party
pharmaceutical companies that enter into collaboration agreements with
the Company and/or GTC with respect to such G Protein-coupled receptors.
I am always frustrated when I search the WO or EPO databases for GENE patents..... there just don't seem to be very many "out there". I presume, but have no solid evidence that the presumption has basis, that patent applications have been filed for full length sequences for all 56 genes. |
